# Ascletis Reports Blood-Sugar Reductions in Midstage Diabetes Trial

The company announced topline findings from a 100-participant U.S. study of investigational ASC30.

By Will Langan | 24X7 News
Published: 2026-10-29T01:05:46.272Z
Updated: 2026-10-29T01:05:46.272Z
Section: Health
Format: News
Canonical: https://24x7news.us/articles/ascletis-asc30-diabetes-phase-two-results-october-28-2026

Ascletis announced October 28 that its experimental once-daily tablet ASC30 reduced a measure of blood sugar compared with placebo in a U.S. Phase II diabetes trial.

The company reported placebo-adjusted HbA1c reductions of 1.7, 1.6 and 1.7 percentage points at 12 weeks for the 40-, 60- and 80-milligram groups, respectively. Participants' average starting HbA1c was 8.3%.

The randomized, double-blind study enrolled 100 people with type 2 diabetes. Its primary endpoint measured HbA1c at 12 weeks, while weight change at 13 weeks was a secondary endpoint.

Ascletis said there were no discontinuations caused by gastrointestinal adverse events and one discontinuation attributed to hiccups. The company reported no drug-related serious adverse events during the study.

These are the developer's topline findings from a relatively small, short trial. They do not establish long-term safety or regulatory approval. ASC30 remains investigational, and the company's separate Phase III obesity program addresses a different development program.

Sources
Ascletis Pharma results announcement, distributed by PR Newswire, October 28, 2026.

## Sources
- Ascletis Results Announcement via StreetInsider: https://www.streetinsider.com/PRNewswire/Ascletis%2BOral%2BSmall%2BMolecule%2BGLP-1%2C%2BASC30%2C%2BDemonstrated%2BPlacebo-Adjusted%2BHbA1c%2BReduction%2Bof%2B1.7%25%2Bat%2B12%2BWeeks%2Bfrom%2BIts%2BU.S.%2BPhase%2BII%2BStudy%2Bin%2BParticipants%2Bwith%2BDiabetes/27250664.html